SCHEMBL677036

SCHEMBL677036

CC(C)([SbH2])c1ccc(C(=O)Oc2ccccc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.66
TDP1 Q9NUW8 2/20 0.66
L3MBTL1 Q9Y468 1/20 0.66
PARP10 Q53GL7 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
PRSS1 P07477 2/20 0.50
ACR P10323 2/20 0.50
TMPRSS15 P98073 2/20 0.50
ALDH1A1 P00352 4/20 0.49
PKM P14618 1/20 0.49
NSD2 O96028 1/20 0.47
THRB P10828 1/20 0.46
ELANE P08246 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TNF P01375 1/20 0.43
KLF5 Q13887 1/20 0.43
NOD1 Q9Y239 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL678424 0.86 MAPT (0.70) MAPTTDP1L3MBTL1PARP10SMN1; SMN2
SCHEMBL1790578 0.86 MAPT (0.87) MAPTTDP1L3MBTL1PARP10SMN1; SMN2
SCHEMBL548358 0.85 MAPT (0.68) MAPTTDP1L3MBTL1PARP10SMN1; SMN2
SCHEMBL5706144 0.85 MAPT (0.68) MAPTTDP1L3MBTL1PARP10SMN1; SMN2
SCHEMBL28679086 0.85 MAPT (0.84) MAPTTDP1L3MBTL1PARP10SMN1; SMN2
SCHEMBL3180097 0.83 MAPT (0.66) MAPTTDP1L3MBTL1PARP10SMN1; SMN2
SCHEMBL27705933 0.83 MAPT (0.66) MAPTTDP1L3MBTL1PARP10SMN1; SMN2
SCHEMBL11682889 0.82 MAPT (0.69) MAPTTDP1L3MBTL1PARP10SMN1; SMN2
SCHEMBL70034 0.82 PARP10 (0.70) MAPTTDP1L3MBTL1PARP10SMN1; SMN2
SCHEMBL2331411 0.81 MAPT (0.62) MAPTTDP1L3MBTL1PARP10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110275774-A1 ORGANOANTIMONY COMPOUND, PROCESS FOR PREPARING SAME, LIVING RADICAL POLYMERIZATION INITIATOR, PROCESS FOR PRODUCING POLYMER WITH USE OF SAME, AND THE POLYMER YAMAGO SHIGERU 2011-11-10 US disclosed
US-8008414-B2 Organic antimony compound, process for producing the same, living radical polymerization initiator, process for producing polymer using the same, and polymer OTSUKA CHEMICAL CO., LTD. (JP) 2011-08-30 US disclosed
EP-1767539-B1 ORGANIC ANTIMONY COMPOUND, PROCESS FOR PRODUCING THE SAME, LIVING RADICAL POLYMERIZATION INITIATOR, PROCESS FOR PRODUCING POLYMER USING THE SAME, AND POLYMER OTSUKA CHEMICAL CO LTD (JP) 2011-07-27 EP disclosed
US-20090299008-A1 Organic antimony compound, process for producing the same, living radical polymerization initiator, process for producing polymer using the same, and polymer OTSUKA CHEMICAL CO., LTD. (JP) 2009-12-03 US disclosed
EP-1767539-A1 ORGANIC ANTIMONY COMPOUND, PROCESS FOR PRODUCING THE SAME, LIVING RADICAL POLYMERIZATION INITIATOR, PROCESS FOR PRODUCING POLYMER USING THE SAME, AND POLYMER OTSUKA CHEMICAL COMPANY, LTD. (JP) 2007-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090299008-A1 Organic antimony compound, process for producing the same, living radical polymerization initiator, process for producing polymer using the same, and polymer AOC2, ODC1, MCM7 MAPT 2424/4885TDP1 2799/4885L3MBTL1 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.